Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

EdiGene Licenses IP to Treat Genetically Caused Hemoglobin Diseases

publication date: Mar 16, 2022

Beijing EdiGene signed a non-exclusive, worldwide license agreement to use IP developed by Boston Children's Hospital for increasing fetal hemoglobin levels. The IP is related to methods and compositions for disrupting BCL11A expression at the genomic level. According to EdiGene, scientific evidence suggests that up-regulating the production of fetal hemoglobin is one way to address genetically caused hemoglobin diseases. EdiGene translates gene-editing technologies into novel therapies for genetic diseases and cancer. The terms of the agreement were not disclosed. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here